In conclusion, we propose that KLK1, KLK2, KLK3 KLK4, KLK8, KLK9, and KLK14, which are differentially expressed in prostate cancer, could be used as promising biomarkers of prostate cancer progression. Here, KLK1 is linked to prostate carcinoma.